Cargando…

Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken?

Detalles Bibliográficos
Autor principal:	Patoulias, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369027/ https://www.ncbi.nlm.nih.gov/pubmed/34447672 http://dx.doi.org/10.14218/JCTH.2021.00236

Ejemplares similares

Serum Resistin Levels in Adult Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
por: Han, Dongli, et al.
Publicado: (2021)

The relationship between resistin and ghrelin levels with fibrosis in nonalcoholic fatty liver disease
por: Eminler, Ahmet Tarık, et al.
Publicado: (2014)

Serum Resistin Level and Its Receptor Gene Expression in Liver Biopsy as Predictors for the Severity of Nonalcoholic Fatty Liver Disease
por: Hegazy, Mona, et al.
Publicado: (2014)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

The Road Not Taken: Commensal or Virulent Pathogen
Publicado: (2020)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Elevated serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
por: Jang, Byoung Kuk
Publicado: (2012)

Hepatic inflammation: an important target for biomarker development in nonalcoholic fatty liver disease
por: Khan, Hiba, et al.
Publicado: (2023)

The road not taken: beyond our embarrassment and skepticism
por: Choi, Jeom-Il
Publicado: (2019)

Diet and Lifestyle in Nonalcoholic Fatty Liver Disease
por: Martínez-Beamonte, Roberto, et al.
Publicado: (2020)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
por: El Ouaamari, Abdelfattah, et al.
Publicado: (2013)

Noninvasive Markers for the Diagnosis of Nonalcoholic Fatty Liver Disease
por: Kim, Sang Yong
Publicado: (2013)

The utility of ezetimibe therapy in nonalcoholic fatty liver disease
por: Jun, Baek Gyu, et al.
Publicado: (2019)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

Treating Nonalcoholic Fatty Liver Disease From the Outside In?
por: Flynn, Charles R.
Publicado: (2019)

Imaging methods in the assessment of nonalcoholic fatty liver disease
por: Parente, Daniella Braz
Publicado: (2020)

Omentin-1 rs2274907 and resistin rs1862513 polymorphisms influence genetic susceptibility to nonalcoholic fatty liver disease
por: Kohan, Leila, et al.
Publicado: (2016)

Obesity, adipocyte hypertrophy, fasting glucose, and resistin are potential contributors to nonalcoholic fatty liver disease in South Asian women
por: Albracht-Schulte, Kembra, et al.
Publicado: (2019)

Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease
por: Zeng, Yuping, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease: Diagnostic biomarkers
por: Hadizadeh, Fatemeh, et al.
Publicado: (2017)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
por: Park, Ji-Won, et al.
Publicado: (2023)

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try
por: Ren, Tian-Yi, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease – a growing public health problem
por: Mikolašević, Ivana, et al.
Publicado: (2021)

Sarcopenia as a Novel Risk Factor for Nonalcoholic Fatty Liver Disease
por: Noh, Junghyun
Publicado: (2020)

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
por: Ahn, Sang Bong
Publicado: (2023)

Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease
por: Tokushige, Katsutoshi, et al.
Publicado: (2013)

Serum miR-4488 as a potential biomarker of lean nonalcoholic fatty liver disease
por: Shen, Nan, et al.
Publicado: (2023)

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease
por: Hwang, Seonghwan, et al.
Publicado: (2022)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management
por: Chrysavgis, Lampros, et al.
Publicado: (2020)

The role of magnetic resonance elastography in the evaluation of nonalcoholic fatty liver disease
por: Idilman, Ilkay S., et al.
Publicado: (2023)

Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis
por: Kang, Seong Hee, et al.
Publicado: (2023)

Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories
por: Kantartzis, Konstantinos, et al.
Publicado: (2023)

Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
por: Chun, Ho Soo
Publicado: (2023)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q16jjh9n2laf8h6iu1m1om27oi